Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Medications in development for PsA.
| Drug | Mechanism of action | Current phase in clinical trials |
|---|---|---|
| Ixekizumab | IL-17A inhibitor | SPIRIT-P2 Phase III (NCT02349295) |
| Abatacept | CTLA4-Ig | Phase III (NCT01860976) |
| Risankizumab | IL-23 inhibitor | Phase II (NCT02986373) |
| Guselkumab | IL-23 inhibitor | Phase II (NCT02319759) |
| Tofacitinib | Oral JAK inhibitor | Phase III (NCT01976364) |
| Tildrakizumab | IL-23 inhibitor | Unknown currently |
CTLA4-Ig: cytotoxic T lymphocyte-associated antigen-4 immunoglobulin fusion protein.
